Cancer Ag, 125

Code

0895

Principle

Serum CA 125 antigen levels may be used as an aid in monitoring the response to therapy for patients with epithelial ovarian carcinoma. The presence of persistently rising CA 125 antigen levels indicate poor response to therapy, whereas decreasing CA 125 antigen levels may indicate a positive therapeutic response. CA 125 antigen levels are elevated in many patients with epithelial ovarian carcinoma. It may also be elevated in diseases other than epithelial ovarian carcinoma, including other benign or malignant ovarian diseases, such as endometriosis, and in lung cancer and in other non-cancerous conditions such as pregnancy.

Preanalytical

1 mL Serum Refrigerated

Turn Around Time

1 day

Methodology

Chemiluminescent immunoassay (CLIA)

Limitations

Patients who have been regularly exposed to animals or have received immunotherapy or diagnostic procedures utilizing immunoglobulins or ummunoglobulin fragments may produce antibodies, e.g. HAMA, that interfere with immunoassays.

All results should be interpreted in light of the total clinical presentation of the patient, including: symptoms, clinical history, data from additional tests and other appropriate information.